Data Support Adjuvant Pembrolizumab as Standard Care in Stage IIB/C Melanoma
Source: Cancer Therapy Advisor, June 2023
Adjuvant pembrolizumab provides a continued benefit for patients with stage IIB or IIC melanoma at 3 years, according to research presented at the ASCO Annual Meeting 2023.
Updated data from the KEYNOTE-716 trial showed that adjuvant pembrolizumab improved distant-metastasis-free survival (DMFS) and recurrence-free survival (RFS) at 3 years, when compared to placebo.
These results support the use of pembrolizumab as standard care for patients with resected stage IIB or IIC melanoma, said study presenter Jason J. Luke, MD, of UPMC Hillman Cancer Center in Pittsburgh, Pennsylvania.